Opinion|Videos|March 27, 2025
FDA-Approved Treatments for BCG-Unresponsive NMIBC
Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec—highlighting how each is administered, and share their impressions of the safety and efficacy of these agents.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Three new treatments for patients who are unresponsive to BCG were FDA approved in the last 5 years. Briefly discuss each of the following approved therapies and how are they are administered.
- Pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec
- What are your impressions of the safety and efficacy of these agents?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
Practical guide to female pelvic organ–sparing radical cystectomy
3
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
4
Targeting BCG resistance in high-risk NMIBC
5